GET STARTED WITH OUR PHARMACY PROVIDER

HAVE A QUESTION? GET IN TOUCH
#1 perscribed oral TRT*

Starting or switching to Jatenzo is easy

Physicians report that 66% of patients switched their TRT in a year1

Jump to:

Switching to JATENZO Titration

DOSING OPTIONS

JATENZO has 5 dosing options to titrate up or down for your new or existing TRT patients2

Recommended starting dose is 237 mg BID. Depending on how your patient responds to JATENZO, his dose may need to be adjusted up or down, and can be titrated as early as eight days after treatment initiation.2

JATENZO makes it easy. Use this helpful tool to individualize his dose based on his serum testosterone concentration.

Each dose is taken twice daily with food (ANY food)2

30-day supply, dispense as written. Refer to the full Prescribing Information for titration instructions.

158 mg BID

198 mg BID

237 mg BID

316 mg BID

396 mg BID

recommended
starting dose

BID=twice a day; PO=per os (by mouth); TRT=testosterone replacement thereapy

Capsules are not actual size.

EASY TO USE TITRATION TOOL

Physicians say almost half of patients require titration after the initial dose1

JATENZO makes it easy. Use this helpful tool to individualize his dose based on his serum testosterone concentration.2

Monitor every 30 days2,3

Within 7 days of starting a new dose, you can evaluate his serum testosterone by testing 4-6 hours after the morning dose to determine if dose should be adjusted.2

Select your current BID dose

396 mg BID

316 mg BID

237 mg BID

Recommended starting dose

198 mg BID

158 mg BID

What level do you see?

Here's your recommended step

TITRATE UP
CONTINUE WITH CURRENT DOSE
TITRATE DOWN
DISCONTINUE TREATMENT.
Re-Test/
Re-Assess
Therapy

*Assess serum concentrations after at least 7 days (4-6 hours after AM dose). Continue to monitor as needed as dose adjustment needs can persist.2

When Prescribing JATENZO

Remember the recommended starting dose: 237 mg
One capsule PO BID. Taken with food (ANY food)2,4

Have a JATENZO question?

Connect with an account manager for support, or request medical information about JATENZO clinical trials and safety.

Connect Now

IMPORTANT SAFETY INFORMATION FOR JATENZO (testosterone undecanoate)

Indication and Limitations of Use:

JATENZO® (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

  • Primary hypogonadism (congenital or acquired)
  • Hypogonadotropic hypogonadism (congenital or acquired)

Safety and efficacy of JATENZO in men with “age-related hypogonadism” and in males less than 18 years old have not been established.

IMPORTANT SAFETY INFORMATION FOR JATENZO (testosterone undecanoate)

CONTRAINDICATIONS

JATENZO is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate, in women who are pregnant, or in men with a known hypersensitivity to JATENZO or its ingredients.

WARNINGS AND PRECAUTIONS

Increase in hematocrit and polycythemia. High red blood cell counts increase the risk of clots, strokes, and heart attacks.

Venous thromboembolic events (VTE). Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone replacement products like JATENZO.

Benign prostatic hyperplasia (BPH). Patients may see worsening signs and symptoms of BPH.

Prostate cancer. Patients treated with androgens may be at increased risk for prostate cancer.

Blood pressure increases. JATENZO can increase blood pressure. Monitor blood pressure periodically in men using JATENZO. Not recommended for use with uncontrolled hypertension.

Abuse. Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Testosterone abuse can lead to serious cardiovascular and psychiatric adverse reactions.

Suppression of spermatogenesis. Large doses of androgens, like JATENZO, can suppress spermatogenesis.

Hepatic adverse events. JATENZO is not known to cause liver adverse events; however, patients should be instructed to report any signs of hepatic dysfunction.

Retention of sodium and water.

Gynecomastia.

Sleep apnea. Testosterone may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease.

Changes in the serum lipid profile may require dose adjustment of lipid-lowering drugs or discontinuation of testosterone therapy.

Risk of hypercalcemia.

ADVERSE EVENTS

The most common adverse events of JATENZO (incidence ≥2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

DRUG INTERACTIONS

JATENZO can cause changes in insulin sensitivity or glycemic control and changes in anticoagulant activity. Use of testosterone and corticosteroids concurrently may increase fluid retention. Use of prescription and nonprescription analgesic cold medications with JATENZO have been known to increase blood pressure.

To report suspected adverse reactions contact Tolmar at 1-844-4TOLMAR (486-5627) or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see full Prescribing Information.

References

1. Data on file. The Landmark SERMO survey: The state of TRT in 2024. (conducted February 16-March 1, 2024). Tolmar, Inc.

2. JATENZO® (testosterone undecanoate) capsules, for oral use CIII [package insert]. Fort Collins, CO: Tolmar, Inc.; 2025.

3.  Swerdloff RS, Dudley RE. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Ther Adv Urol. 2020;12:1-16.

4. Swerdloff RS, Wang C, White WB, et al. A new oral testosterone undecanoate formulation restores testosterone to normal concentrations in hypogonadal men. J Clin Endocrinol Metab. 2020;105(8):2515-2531.